Kymera Therapeutics (KYMR) Other Non-Current Liabilities (2020 - 2023)
Kymera Therapeutics (KYMR) posted quarterly Other Non-Current Liabilities of $8000.0 for Q3 2023, down 96.88% year-over-year from $256000.0 in Q3 2022, and down 96.52% quarter-over-quarter from $230000.0 in Q2 2023.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Other Non-Current Liabilities (2020 - 2023) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Other Non-Current Liabilities for 4 consecutive years, with $8000.0 the latest figure, recorded in Q3 2023.
- In Q3 2023, Other Non-Current Liabilities fell 96.88% year-over-year to $8000.0; the TTM figure through Sep 2023 stood at $8000.0 (down 96.88% YoY), while the FY2022 annual figure was $248000.0, up 275.76% from the prior year.
- Other Non-Current Liabilities eased to $8000.0 in Q3 2023 per KYMR's latest filing, from $230000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $273000.0 in Q1 2022 and bottomed at $8000.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $161166.7 across 4 years, with a median of $165000.0 in 2020.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 275.76% — and 2023, when it plunged 96.88%.
- Kymera Therapeutics' Other Non-Current Liabilities stood at $100000.0 in 2020, then tumbled by 34.0% to $66000.0 in 2021, then jumped by 275.76% to $248000.0 in 2022, then plunged by 96.77% to $8000.0 in 2023.
- Business Quant data shows KYMR's Other Non-Current Liabilities at $8000.0 in Q3 2023, $230000.0 in Q2 2023, and $237000.0 in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | 8,000.00 |
| Jun 30, 2023 | 230,000.00 |
| Mar 31, 2023 | 237,000.00 |
| Dec 31, 2022 | 248,000.00 |
| Sep 30, 2022 | 256,000.00 |
| Jun 30, 2022 | 264,000.00 |
| Mar 31, 2022 | 273,000.00 |
| Dec 31, 2021 | 66,000.00 |
| Sep 30, 2021 | 76,000.00 |
| Jun 30, 2021 | 84,000.00 |
| Mar 31, 2021 | 92,000.00 |
| Dec 31, 2020 | 100,000.00 |